# Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT05986591** · PHASE3 · COMPLETED · sponsor: **Xiromed LLC** · enrollment: 335 (actual)

## Conditions studied

- COPD

## Interventions

- **COMBINATION_PRODUCT:** Test Product - Tiotropium Bromide Inhalation Powder 18 mcg
- **COMBINATION_PRODUCT:** Spiriva Handihaler (Tiotropium Bromide) 18 mcg
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT05986591
- **Lead sponsor:** Xiromed LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-17
- **Primary completion:** 2023-08-11
- **Final completion:** 2023-08-14
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2024-01-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05986591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05986591, "Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05986591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*